Pharmacy Medical News about Acute Coronary Syndrome Platelet Aggregation Inhibitors

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Antiplatelet Intervention in Acute Coronary Syndrome
American Journal of Therapeutics, 09/29/09

Arora RR et al. – Data from CRUSADE suggests that the majority of patients are likely to benefit from aggressive upstream antithrombotic therapy. Patients with ACS who have diabetes have a higher risk for recurrent events than their nondiabetic counterparts but stand to benefit more from early aggressive therapy. Combining GP IIb/IIIa inhibition with drug–eluting stents offers the potential to optimize outcomes after revascularization in patients with diabetes. Whereas the use of drug–eluting stents has greatly reduced the risk of restenosis, patients with diabetes who have ACS and who undergo stenting remain at high risk for restenosis and are more likely to require revascularization. Increasing adherence to American College of Cardiology/American Heart Association guidelines is key to improving outcomes. The optimal management of patients with ACS continues to change as new therapies and strategies of care are developed and proven effective. The clinical challenge remains to increase physician adherence to evidence–based cardiac care for all patients.

<< Previous
Cancer pain therapy

Next >>
Phospholipase A2 inhibitors in the treatment of atherosclerosis:...